Regulatory Network in Protein Phosphorylation
[Home] [About] [Browse Kinome] [Phosphorylation Prediction] [Expression Analysis] [Statistics] [Help] Version 1.0

[Back to Kinase PKN2]
Substrate: CDC25C

Description: M-phase inducer phosphatase 3 (EC (Dual specificityphosphatase Cdc25C).

Ensembl ID: ENSG00000158402

UniprotKB/SwissProt: MPIP3_HUMAN (P30307)

Function: Functions as a dosage-dependent inducer in mitotic control. It is a tyrosine protein phosphatase required for progression of the cell cycle. It directly dephosphorylates CDC2 and activate its kinase activity.

Other Modifications: View all modification sites in dbPTM

Protein Subcellular Localization: Nucleus.
Protein Domain and Phosphorylation Sites:

The phosphorylated sites of CDC25C

No.SubstrateUniProtKB IDPositionPhosphoPeptideSolvent AccessibilityCatalytic kinaseSourceComputational Annotation of Catalytic KinaseInteracting PartnersExpression Analysis
1CDC25CMPIP3_HUMANT48PDVPR T PVGKF 19.09%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
2CDC25CMPIP3_HUMANT48PDVPR T PVGKF 19.09%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
3CDC25CMPIP3_HUMANT67ILSGG T PKRCL 29.21%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
4CDC25CMPIP3_HUMANT67ILSGG T PKRCL 29.21%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
5CDC25CMPIP3_HUMANS122HLMKC S PAQLL 20.11%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
6CDC25CMPIP3_HUMANS122HLMKC S PAQLL 20.11%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
7CDC25CMPIP3_HUMANT130QLLCS T PNGLD 21.56%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
8CDC25CMPIP3_HUMANT130QLLCS T PNGLD 21.56%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
9CDC25CMPIP3_HUMANS168MKYLG S PITTV 15.55%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
10CDC25CMPIP3_HUMANS168MKYLG S PITTV 15.55%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
11CDC25CMPIP3_HUMANS168MKYLG S PITTV 15.55%JNK2(MAPK9) Phospho.ELM 7.0 ViewAnalyzing
12CDC25CMPIP3_HUMANS168MKYLG S PITTV 15.55% Swiss-Prot 55.0 View   
13CDC25CMPIP3_HUMANS191QAEEI S DELME 28.45%PLK3 Phospho.ELM 7.0  ViewAnalyzing
14CDC25CMPIP3_HUMANS198ELMEF S LKDQE 22.62%PLK3 Phospho.ELM 7.0  ViewAnalyzing
15CDC25CMPIP3_HUMANS198ELMEF S LKDQE 22.62%PLK1 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
16CDC25CMPIP3_HUMANS198ELMEF S LKDQE 22.62%PLK1 Phospho.ELM 7.0  ViewAnalyzing
17CDC25CMPIP3_HUMANS214SGLYR S PSMPE 14.04%CDC2 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
18CDC25CMPIP3_HUMANS214SGLYR S PSMPE 14.04%CDC2(CDK1) Phospho.ELM 7.0 ViewAnalyzing
19CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%BRSK1 Swiss-Prot 55.0   ViewAnalyzing
20CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%CHK1 HPRD:01146(in vitro)  ViewAnalyzing
21CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%CHK2 Swiss-Prot 55.0   ViewAnalyzing
22CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%CHK1 Swiss-Prot 55.0   ViewAnalyzing
23CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%CHK2 HPRD:01146(in vitro)  ViewAnalyzing
24CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%CHK2 Phospho.ELM 7.0  ViewAnalyzing
25CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%PKN1 HPRD:01146(in vitro)  ViewAnalyzing
26CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%PLK3 HPRD:01146(in vitro)  ViewAnalyzing
27CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%p38a HPRD:01146(in vitro)  ViewAnalyzing
28CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%BRSK2 HPRD:01146(in vitro)  ViewAnalyzing
29CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%BRSK1 Phospho.ELM 7.0  ViewAnalyzing
30CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%MARK3 HPRD:01146(in vitro;in vivo)  ViewAnalyzing
31CDC25CMPIP3_HUMANS216LYRSP S MPENL 48.49%BRSK1 HPRD:01146(in vitro;in vivo)  ViewAnalyzing